Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

Sofia Agelaki,A. Kalykaki,Harris Markomanolaki,Maria Papadaki,Galatea Kallergi,Dora Hatzidaki,K. Kalbakis,D. Mavroudis,Vassilis Georgoulias

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

2015

Sofia Agelaki
A. Kalykaki
Harris Markomanolaki
Maria Papadaki
Galatea Kallergi
Dora Hatzidaki
K. Kalbakis
D. Mavroudis
Vassilis Georgoulias

Background To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC).

Keywords:

Breast cancer
CA15-3
Circulating tumor cell
Lapatinib
Metastasis
Hormonal therapy
Tyrosine-kinase inhibitor
Immunology
Cancer research
Medicine
Metastatic breast cancer
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations